ERBB2 and breast cancer: The phase III MONARCH-plus trial with abemaciclib and nonsteroidal aromatase inhibitor (NSAI) or fulvestrant treatment showed improved PFS in predominantly Chinese postmenopausal women with ER+/HER2 breast cancer (Jiang et al., 2019a).